Retour
Prix Bioxytran Inc (BIXT)
Graphique du cours de l'action BIXT
BIXT Gagner
Bioxytran Inc
$0.04
-0.2%
$0
À la fermeture : Feb 13, 16:00:00 GMT-5
$0.04
0%
$0
Post-Marché: Feb 13, 20:00:00 GMT-5
Pas encore de donnéesEarnings FAQ
Comment le bénéfice par action récent de BIXT se compare-t-il aux attentes ?
Comment les revenus de Bioxytran Inc BIXT se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Bioxytran Inc ?
Quel est le score de qualité des bénéfices pour Bioxytran Inc ?
Quand Bioxytran Inc publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Bioxytran Inc ?
Bioxytran Inc a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$0.049
Prix d'ouverture
$0.0489
Plage de la journée
$0.0477 - $0.0489
Plage de 52 semaines
$0.0342 - $0.2283
Volume
7.5K
Volume moyen
174.7K
BPA (TTM)
-0.02
Rendement en dividend
--
Capitalisation boursière
$4.8M
Qu’est-ce que BIXT ?
BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. The company is headquartered in Needham, Massachusetts. The company went IPO on 2010-01-05. The firm is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The firm's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.